CMP Therapeutics appoints Dr Neill Moray Mackenzie

pharmafile | August 9, 2010 | Appointment | Research and Development CMP Therapeutics, appointment, research and development 

Dr Neill Moray Mackenzie has joined Hertfordshire, UK-based biopharmaceutical company CMP Therapeutics as chief executive.

He has a long record of executive board level management at companies that include Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, Medigene, where he was senior vice president for business development and corporate strategy.

Dr MacKenzie has also served as a departmental head in vaccine R&D at Wellcome and as a Wellcome Lecturer in Immunology at the University of London.

Advertisement

Dr Achim Kaufhold, chairman of CMP, said: “Now is a pivotal time for the company as we move into advanced clinical development for our lead product and we are delighted to welcome Dr Mackenzie as chief executive.

“He combines proven experience in driving the corporate development of spin-outs from the Universities of Cambridge and Oxford with a highly relevant academic background in immunology and is ideally placed to ensure the rapid realisation of the value of our ground breaking technology.”

Meanwhile, CMP’s former chief executive Dr Bruce Savage leaves to concentrate on his other portfolio companies.

Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025

The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy

Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …

The Gateway to Local Adoption Series

Latest content